• Something wrong with this record ?

Mifepristone potentiates etoposide toxicity in Hep G2 cells by modulating drug transport

Z. Dostál, P. Kosina, P. Mlejnek, K. Kikalová, M. Modrianský,

. 2019 ; 54 (-) : 33-40. [pub] 20180912

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19012377

Etoposide is a well-known and widely used anticancer drug that displays several side effects. In addition, tumors often acquire resistance to this drug. Our aim is to develop a combination therapy that would augment toxicity of etoposide in malignant cells. Based on literature and our experiments, we selected mifepristone (RU486) as a potential supporting molecule that is able to enhance etoposide toxicity against cancer cells. All experiments were performed with Hep G2 cells, a well-known and described human hepatocellular carcinoma cell line. By using xCELLigence system, we demonstrated that mifepristone enhances toxicity of etoposide in a dose dependent manner with concomitant caspase-3 activity. We evaluated upregulation of Bax because mifepristone was demonstrated to modulate proapoptotic Bax protein expression. Our data show only weak and not statistically significant increase of Bax expression. On the other hand, we show that mifepristone increases etoposide toxicity via inhibition of ABC transporters, coupled with significant increase of intracellular etoposide concentration. In conclusion, we demonstrate that mifepristone has a synergistic effect with etoposide treatment in the Hep G2 cells and that the effect is related to ABC transporters inhibition.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012377
003      
CZ-PrNML
005      
20211221135729.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.tiv.2018.09.005 $2 doi
035    __
$a (PubMed)30217652
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dostál, Zdeněk $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. $7 xx0267686
245    10
$a Mifepristone potentiates etoposide toxicity in Hep G2 cells by modulating drug transport / $c Z. Dostál, P. Kosina, P. Mlejnek, K. Kikalová, M. Modrianský,
520    9_
$a Etoposide is a well-known and widely used anticancer drug that displays several side effects. In addition, tumors often acquire resistance to this drug. Our aim is to develop a combination therapy that would augment toxicity of etoposide in malignant cells. Based on literature and our experiments, we selected mifepristone (RU486) as a potential supporting molecule that is able to enhance etoposide toxicity against cancer cells. All experiments were performed with Hep G2 cells, a well-known and described human hepatocellular carcinoma cell line. By using xCELLigence system, we demonstrated that mifepristone enhances toxicity of etoposide in a dose dependent manner with concomitant caspase-3 activity. We evaluated upregulation of Bax because mifepristone was demonstrated to modulate proapoptotic Bax protein expression. Our data show only weak and not statistically significant increase of Bax expression. On the other hand, we show that mifepristone increases etoposide toxicity via inhibition of ABC transporters, coupled with significant increase of intracellular etoposide concentration. In conclusion, we demonstrate that mifepristone has a synergistic effect with etoposide treatment in the Hep G2 cells and that the effect is related to ABC transporters inhibition.
650    _2
$a P-glykoproteiny $x antagonisté a inhibitory $7 D018435
650    _2
$a ABC transportér z rodiny G, člen 2 $x antagonisté a inhibitory $7 D000070997
650    _2
$a fytogenní protinádorové látky $x farmakologie $7 D000972
650    _2
$a biologický transport $x účinky léků $7 D001692
650    _2
$a kaspasa 3 $x metabolismus $7 D053148
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a synergismus léků $7 D004357
650    _2
$a etoposid $x farmakologie $7 D005047
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a mifepriston $x farmakologie $7 D015735
650    _2
$a nádorové proteiny $x antagonisté a inhibitory $7 D009363
650    _2
$a protein X asociovaný s bcl-2 $x metabolismus $7 D051028
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kosina, P $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
700    1_
$a Mlejnek, P $u Department of Anatomy, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
700    1_
$a Kikalová, K $u Department of Anatomy, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
700    1_
$a Modrianský, M $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic. Electronic address: martin.modriansky@upol.cz.
773    0_
$w MED00004536 $t Toxicology in vitro an international journal published in association with BIBRA $x 1879-3177 $g Roč. 54, č. - (2019), s. 33-40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30217652 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20211221135724 $b ABA008
999    __
$a ok $b bmc $g 1391687 $s 1050682
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 54 $c - $d 33-40 $e 20180912 $i 1879-3177 $m Toxicology in vitro $n Toxicol In Vitro $x MED00004536
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options